ZLDPF (ZLDPF) Stock Price & Analysis
ZLDPF (ZLDPF) fell 2.66% to USD 46.38 as of September 9, 2026 at 22:08 UTC, according to Nexqual real-time market data.
ZLDPF last closed at USD 47.64; the session ranged USD 46.61–46.61 on volume of 3,000 shares. Market capitalization is $3.14B, with a 52-week range of USD 35.93–83.12 (PNK). Source: Nexqual, September 9, 2026 at 22:08 UTC.
Key Statistics (as of September 9, 2026 at 22:08 UTC)
| Price | USD 46.38 |
|---|---|
| Change | ▼ 2.66% (down) |
| Previous Close | USD 47.64 |
| Open | USD 46.61 |
| Day Range | USD 46.61 – 46.61 |
| 52-Week Range | USD 35.93 – 83.12 |
| Volume | 3,000 shares |
| Market Cap | $3.14B |
| Exchange | PNK |
Technical Analysis (ZLDPF)
Nexqual's technical model rates ZLDPF "SELL" based on 1 bullish and 5 bearish signals across 126 daily candles, as of September 9, 2026 at 22:08 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.21 (neutral) |
| vs SMA50 | Below (USD 47.3) |
| MACD | -0.2 (negative) |
Analyst Ratings (ZLDPF)
Wall Street analysts rate ZLDPF "None", per Nexqual as of September 9, 2026 at 22:08 UTC.
| Consensus Rating | None |
|---|
Earnings (ZLDPF)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $119.12M |
Source: Nexqual, September 9, 2026 at 22:08 UTC.
Financials & Fundamentals (ZLDPF)
| Total Revenue | $4.64B |
|---|---|
| Revenue Growth (YoY) | -50.60% |
| Gross Margin | +100.00% |
| Operating Margin | +85.93% |
| Profit Margin | +59.02% |
| ROE | +16.31% |
| Debt / Equity | 2.28 |
| Current Ratio | 13.98 |
| Total Cash | $14.46B |
| Total Debt | $411.00M |
| Free Cash Flow | $-2.06B |
Source: Nexqual, September 9, 2026 at 22:08 UTC.
Financial Health Score (ZLDPF)
Nexqual rates ZLDPF's overall financial health "Solid" across five dimensions, as of September 9, 2026 at 22:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Strong — Operating margin 86% |
| Balance Sheet | Strong — $14.5B cash vs $411M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$2.06B, burning cash |
| Efficiency | Solid — ROE 16%, ROA 7.8% |
Ownership (ZLDPF)
| Insider Ownership | +0.53% |
|---|---|
| Institutional Ownership | +40.62% |
| Shares Outstanding | 67.66M |
| Float | 55.17M |
Source: Nexqual, September 9, 2026 at 22:08 UTC.
Leadership (ZLDPF)
ZLDPF is led by Adam Sinding Steensberg (age 51), President & CEO, per Nexqual as of September 9, 2026 at 22:08 UTC.
| President & CEO | Adam Sinding Steensberg (age 51) |
|---|---|
| EVP & CFO | Henriette Wennicke (age 42) |
| Executive VP & COO | Ivan Mourits Moller |
| Executive VP & Chief Scientific Officer | Utpal Singh (age 51) |
Major Backers & Investors (ZLDPF)
Notable institutional backers of ZLDPF include EuroPacific Growth Fund-EUPAC Fund, SmallCap World Fund Inc, Fidelity, according to Nexqual as of September 9, 2026 at 22:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EuroPacific Growth Fund-EUPAC Fund | 2.56% |
| SmallCap World Fund Inc | 1.6% |
| Fidelity | 1.31% |
| American Century ETF Trust-Avantis International Small Cap Value ETF | 0.89% |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 0.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.88% |
| BlackRock | 0.67% |
Source: Nexqual, September 9, 2026 at 22:08 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BVNKF | Bavarian Nordic A/S | USD 32.57 | ▲ 0% |
| BFFAF | BASF SE | USD 62 | ▲ 0% |
| TLPPF | Telix Pharmaceutical Ltd. | USD 10.99 | ▲ 0% |
| IVBXF | Innovent Biologics Inc. | USD 13.19 | ▲ 0.57% |
| ARGNF | ARGENX SE | USD 1,010.26 | ▼ 0.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 22:08 UTC. This page is informational and not investment advice.